Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1

Journal of Parkinson's Disease

Volumn 7, Issue 1, 2017, Pages 117-127

  Hauser, Robert A ^a   Li, Ruosha ^b   Pérez, Adriana ^b   Ren, Xuehan ^b   Weintraub, Dan ^c   Elm, Jordan ^d   Goudreau, John L ^e   Morgan, John C ^f   Fang, John Y ^g   Aminoff, Michael J ^h   Christine, Chadwick W ^h   Dhall, Rohit ⁱ   Umeh, Chizoba C ^j   Boyd, James T ^k   Stover, Natividad ^l   Leehey, Maureen ^m   Zweig, Richard M ⁿ   Nicholas, Anthony P ^o   Bodis Wollner, Ivan ^p   Willis, Allison ^c   Kieburtz, Karl ^q   Tilley, Barbara C ^b   more..

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e East Lansing   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ PARKINSON S INSTITUTE   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF VERMONT   (United States)

^l University of Alabama at Birmingham   (United States)

^m UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁿ Louisiana State University Health Sciences Center at Shreveport   (United States)

^o UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^p SUNY DOWNSTATE MEDICAL CENTER   (United States)

^q UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

disease modification; MAO B inhibitor; Parkinson's disease; rasagiline; selegiline; treatment

Indexed keywords

LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; RASAGILINE; SAFINAMIDE; SELEGILINE; TRANYLCYPROMINE; MONOAMINE OXIDASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PARKINSON DISEASE; RANKIN SCALE; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

AGED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 85012149148     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-160965     Document Type: Article

References (20)

1. Magyar K, Pálfi M, Jenei V, & Szöko E (2006) Deprenyl: From chemical synthesis to neuroprotection. J Neural Transm Suppl, 71,143-156.
2. Weinreb O, Amit T, Riederer P, Youdim MB, & Mandel SA (2011) Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Int Rev Neurobiol, 100,127-149.
3. Sadeghian M, Mullali G, Pocock JM, Piers T, Roach A, & Smith KJ (2016) Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. Neu-ropathol Appl Neurobiol, 42,423-435.
4. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med, 321,1364-1371.
5. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, & ADAGIO Study Investigators (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med, 361,1268-1278.
6. Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R, & Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology, 66,1200-1206.
7. Larsen JP, Boas J, &Erdal JE (1999) Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. Eur J Neurol, 6,539-547.
8. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahod-wala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, SudarskyL, TannerCM, Umeh CC, Williams K, & Wills AM (2015) Effect of creatine mono-hydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial. JAMA, 313,584-593.
9. Elm JJ, & NINDS NET-PD Investigators (2012) Design innovations and baseline findings in a long-term Parkinson's trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord, 27,1513-1521.
10. Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kieburtz K, & Parkinson Study Group (2009) Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord, 24,1732-1739.
11. Bega D, Kim SE, Zhang Y, Elm J, Schneider J, Hauser R, Fraser A, Simuni T, & on behalf of the NET-PD LS1 Investigators (2015) Predictors of functional decline in early Parkinson's disease: NET-PDLS1 Cohort.J ParkinsonsDis, 5,773-782.
12. Schwab R, & England A (1969) Projection technique for evaluating surgery in Parkinson's disease. In Third Symposium on Parkinson's Disease, Gillingham F, Donaldson I, eds. E & S Livingstone, Edinburgh, Scotland, pp. 152-157.
13. Peto V, Jenkinson C, Fitzpatrick R, & Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res, 4,241-248.
14. Fahn S, Elton R, & UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In Recent Developments in Parkinson's Disease, Marsden S, Calne D, Goldstein M, eds. Macmillan Healthcare Information, Florham Park, NJ, pp. 153-163.
15. Smith A (2002) Symbol Digit Modalities Test Manual, Western Psychological Services, Los Angeles, CA.
16. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, & van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19,604-607.
17. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, & Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord, 25,2649-2653.
18. Wills AM, Pérez A, Wang J, Su X, Morgan J, Rajan SS, Leehey M, Pontone GM, Chou K, Umeh C, MariZ, Boyd J, & for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators (2016) Associationbetween change in body mass index, Unified Parkinson Disease Rating Scale scores, and survival among persons with Parkinson disease. Secondary analysis of longitudinal data from NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. JAMA Neurol, 73,321-328.
19. Guo SY, & Fraser MW (2014) Propensity Score Analysis: Statistical Methods and Applications, Second Edition. SAGE publications, pp. 448.
20. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group (1997) A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. Stroke, 28,1530-1540.